illegal pricing

LONDON, UK: The Competition and Markets Authority (CMA) has provisionally found that Pfizer and Flynn abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case. Having gathered further evidence and after carefully assessing the…